摘要:
springer.com
sci-hub.se 参考文章(11)
J. O'Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, G. Monaghan, C. Rocha, V. Ossovskaya, B. Sherman, C. Bradley, G2 Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized phase II trial Ejc Supplements. ,vol. 7, pp. 7- ,(2009) , 10.1016/S1359-6349(09)72040-3
A. Tutt, M. Robson, J. E. Garber, S. Domchek, M. W. Audeh, J. N. Weitzel, M. Friedlander, J. Carmichael, Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.CRA501
George A. Poultsides, Elliot L. Servais, Leonard B. Saltz, Sujata Patil, Nancy E. Kemeny, Jose G. Guillem, Martin Weiser, Larissa K.F. Temple, W. Douglas Wong, Phillip B. Paty, Outcome of Primary Tumor in Patients With Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment Journal of Clinical Oncology. ,vol. 27, pp. 3379- 3384 ,(2009) , 10.1200/JCO.2008.20.9817
E. Van Cutsem, Y. Kang, H. Chung, A. Sawaki, F. Lordick, J. Hill, M. Lehle, A. Feyereislova, Y. Bang, Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC) Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.LBA4509
J. O'Shaughnessy, C. Osborne, J. Pippen, M. Yoffe, D. Patt, G. Monaghan, C. Rocha, V. Ossovskaya, B. Sherman, C. Bradley, Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial Journal of Clinical Oncology. ,vol. 27, pp. 3- 3 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.3
N. Wolmark, G. Yothers, M. J. O'Connell, S. Sharif, J. N. Atkins, T. E. Seay, L. Feherenbacher, S. O'Reilly, C. J. Allegra, A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08 Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.LBA4
E. P. Mitchell, M. Lacouture, H. Shearer, N. Iannotti, B. Piperdi, M. Pillai, F. Xu, M. Yassine, Final STEPP results of prophylacatic versus reactive skin toxicity (ST) treatment (tx) for panitumumab (pmab)-related ST in patients (pts) with metastatic colorectal cancer (mCRC) Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.CRA4027
D. J. Schwartzentruber, D. Lawson, J. Richards, R. M. Conry, D. Miller, J. Triesman, F. Gailani, L. B. Riley, D. Vena, P. Hwu, A phase III multi-institutional randomized study of immunization with the gp100: 209–217(210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma Journal of Clinical Oncology. ,vol. 27, ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.CRA9011
S. J. Schuster, S. S. Neelapu, B. L. Gause, F. M. Muggia, J. P. Gockerman, E. M. Sotomayor, J. N. Winter, C. R. Flowers, A. M. Stergiou, L. W. Kwak, Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results Journal of Clinical Oncology. ,vol. 27, pp. 2- 2 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.2
G. J. Rustin, M. E. van der Burg, A randomized trial in ovarian cancer (OC) of early treatment of relapse based on CA125 level alone versus delayed treatment based on conventional clinical indicators (MRC OV05/EORTC 55955 trials) Journal of Clinical Oncology. ,vol. 27, pp. 1- 1 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.1